AIRLINK 72.59 Increased By ▲ 3.39 (4.9%)
BOP 4.99 Increased By ▲ 0.09 (1.84%)
CNERGY 4.29 Increased By ▲ 0.03 (0.7%)
DFML 31.71 Increased By ▲ 0.46 (1.47%)
DGKC 80.90 Increased By ▲ 3.65 (4.72%)
FCCL 21.42 Increased By ▲ 1.42 (7.1%)
FFBL 35.19 Increased By ▲ 0.19 (0.54%)
FFL 9.33 Increased By ▲ 0.21 (2.3%)
GGL 9.82 Increased By ▲ 0.02 (0.2%)
HBL 112.40 Decreased By ▼ -0.36 (-0.32%)
HUBC 136.50 Increased By ▲ 3.46 (2.6%)
HUMNL 7.14 Increased By ▲ 0.19 (2.73%)
KEL 4.35 Increased By ▲ 0.12 (2.84%)
KOSM 4.35 Increased By ▲ 0.10 (2.35%)
MLCF 37.67 Increased By ▲ 1.07 (2.92%)
OGDC 137.75 Increased By ▲ 4.88 (3.67%)
PAEL 23.41 Increased By ▲ 0.77 (3.4%)
PIAA 24.55 Increased By ▲ 0.35 (1.45%)
PIBTL 6.63 Increased By ▲ 0.17 (2.63%)
PPL 125.05 Increased By ▲ 8.75 (7.52%)
PRL 26.99 Increased By ▲ 1.09 (4.21%)
PTC 13.32 Increased By ▲ 0.24 (1.83%)
SEARL 52.70 Increased By ▲ 0.70 (1.35%)
SNGP 70.80 Increased By ▲ 3.20 (4.73%)
SSGC 10.54 No Change ▼ 0.00 (0%)
TELE 8.33 Increased By ▲ 0.05 (0.6%)
TPLP 10.95 Increased By ▲ 0.15 (1.39%)
TRG 60.60 Increased By ▲ 1.31 (2.21%)
UNITY 25.10 Decreased By ▼ -0.03 (-0.12%)
WTL 1.28 Increased By ▲ 0.01 (0.79%)
BR100 7,566 Increased By 157.7 (2.13%)
BR30 24,786 Increased By 749.4 (3.12%)
KSE100 71,902 Increased By 1235.2 (1.75%)
KSE30 23,595 Increased By 371 (1.6%)
World

Frantic scramble for Covid drugs in India

  • In the same queue in the south of the Indian capital are more than 100 people with loved ones in hospital. Only 30 people receive the medicine.
Published April 27, 2021

NEW DELHI: Manish Aggarwal celebrates with weary relief after laying his hands on precious doses of Covid-19 medication for his sick father -- a victory where thousands across India have not been so lucky.

He has been waiting in line outside a small pharmacy in Delhi for eight hours to secure remdesivir, and is rewarded with just two of the recommended six doses.

"Finally, it's a victory!" he exclaims.

But not everybody is as fortunate.

In the same queue in the south of the Indian capital are more than 100 people with loved ones in hospital. Only 30 people receive the medicine.

Scuffles break out every few minutes as people try to jump the queue. Three armed policemen are stationed nearby for crowd control.

The officers keep telling those gathered that no more tokens -- pieces of paper with a scribbled number on them -- for remdesivir will be distributed today as stocks have run out, and they ask them to try somewhere else.

India is struggling with a catastrophic surge in coronavirus infections as well as severe shortages of medical supplies, with hospitals and crematoriums overwhelmed.

"This government has failed us so much that those who can normally survive also die," says an exhausted Vinod Kumar, who has been waiting since 6 am.

He has also had to battle to obtain oxygen for his sick relative.

As evening falls and the medical supplier -- one of the few places in Delhi where remdesivir is sold at its retail price -- shuts up his shop, some people outside start crying.

They include a brother and sister in their teens who have been driving around looking for medication for their sick and hospitalised father.

Despite India's status as the "pharmacy of the world", the biggest producer of generic drugs has been unable to meet the demand for antiviral medication such as remdesivir.

Many doctors say remdesivir is not essential for the treatment of Covid-19, but hospitals have been prescribing it anyway.

Due to the shortages, families are being asked to procure it on their own.

Many resort to the black market where the drug is sold for anywhere between $300 and $1,350 for a single vial. The usual price is between $12 and $75.

"When I asked someone for six injections, he said, 'I can give you 600, you just need to pay me 60,000 rupees ($800) per injection,'" says Aggarwal.

His fight is not over -- tomorrow he has to hit the streets again in search of more, until all six doses of remdesivir are administered to his father.

"Our patients are suffering in the hospital and we are suffering on the road," he says.

Comments

Comments are closed.